Direct or early discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: Place of therapy of Dalbavancin.
Alessandra OlivaSergio CarbonaraVito CianciMassimo CrapisGino Di Domenico EneaMarco FalconeGioacchino GalardoEmanuele Durante MangoniMario VendittiPublished in: Expert review of anti-infective therapy (2023)
Authors' expert opinion was focused on drawing the profiles of patients who could benefit most from an antimicrobial therapy with dalbavancin in the ED and positioning this drug as a direct or early discharge strategy from the ED in order to avoid hospitalization and its complications. We have provided a therapeutic and diagnostic algorithm based on evidence from the literature and authors' expert opinion and suggest the use of dalbavancin in patients with ABSSSIs who are not eligible for oral therapies or Outpatient Parenteral Antibiotic Therapy (OPAT) programs and who would have otherwise been hospitalized only for antibiotic therapy.
Keyphrases
- emergency department
- systematic review
- end stage renal disease
- ejection fraction
- chronic kidney disease
- public health
- staphylococcus aureus
- liver failure
- stem cells
- machine learning
- prognostic factors
- clinical practice
- cell therapy
- soft tissue
- deep learning
- risk factors
- wound healing
- patient reported outcomes
- electronic health record